Skip to main content

Table 1 Baseline characteristics of the study population

From: Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer

Characteristic

Overall

High LCR

Low LCR

p-value

 

N = 2424

N = 1387

N = 1037

 

Sex, male, n (%)

1457 (60.1)

902 (65.0)

555 (53.5)

 < 0.001

Age, years, mean (SD)

60.18 (11.18)

62.00 [54.00, 68.00]

60.00 [52.00, 66.00]

 < 0.001

BMI, mean (SD)

22.09 (3.13)

21.90 [19.70, 24.10]

22.30 [20.10, 24.60]

0.002

PGSGA (median [IQR])

6.83 (5.12)

7.00 [4.00, 11.00]

4.00 [2.00, 8.00]

 < 0.001

KPS (median [IQR])

82.60 (13.84)

80.00 [70.00, 90.00]

90.00 [80.00, 90.00]

 < 0.001

TP (median [IQR])

68.40 (7.04)

68.00 [63.05, 73.00]

69.30 [65.00, 73.40]

 < 0.001

Scr (median [IQR])

69.89 (33.62)

65.40 [54.40, 79.00]

65.75 [55.90, 78.00]

0.803

Alb (median [IQR])

38.17 (5.08)

36.80 [33.35, 40.00]

40.50 [37.70, 43.00]

 < 0.001

Tch (median [IQR])

4.63 (1.22)

4.36 [3.73, 5.14]

4.66 [4.01, 5.39]

 < 0.001

CRP (median [IQR])

23.63 (38.74)

21.30 [9.57, 51.65]

3.02 [1.31, 3.24]

 < 0.001

Glu (median [IQR])

5.86 (1.95)

5.47 [4.86, 6.40]

5.26 [4.80, 5.97]

 < 0.001

Hb (median [IQR])

119.85 (29.05)

120.00 [102.00, 134.00]

130.00 [115.00, 140.00]

 < 0.001

N (median [IQR])

4.82 (3.33)

4.80 [3.40, 6.66]

3.40 [2.57, 4.64]

 < 0.001

L (median [IQR])

1.49 (0.82)

1.25 [0.90, 1.67]

1.59 [1.24, 1.97]

 < 0.001

RBC (median [IQR])

6.06 (82.34)

4.07 [3.58, 4.53]

4.30 [3.91, 4.69]

 < 0.001

PLT (median [IQR])

237.93 (98.06)

239.00 [175.50, 305.00]

213.00 [168.00, 268.00]

 < 0.001

Lung cancer, yes, n (%)

917 (37.8)

539 (38.9)

378 (36.5)

 < 0.001

Gastric cancer, yes, n (%)

276 (11.4)

155 (11.2)

121 (11.7)

 < 0.001

Liver cancer, yes, n (%)

92 (3.8)

63 (4.5)

29 (2.8)

 < 0.001

Breast cancer, yes, n (%)

136 (5.6)

53 (3.8)

83 (8.0)

 < 0.001

Esophageal cancer, yes, n (%)

156 (5.95)

91 (6.5)

65 (6.2)

 < 0.001

Gynecological tumor, yes, n (%)

67 (2.8)

40 (2.9)

27 (2.6)

 < 0.001

Urinary cancer, yes, n (%)

62 (2.5)

40 (2.8)

22 (2.1)

 < 0.001

Pancreatic cancer, yes, n (%)

97 (4.0)

57 (4.1)

40 (3.9)

 < 0.001

Nasopharyngeal cancer, yes, n (%)

52 (2.1)

24 (1.7)

28 (2.7)

 < 0.001

Colorectal cancer, yes, n (%)

396 (16.3)

206 (14.9)

190 (18.3)

 < 0.001

Biliary Tract cancer, yes, n (%)

36 (1.5)

31 (2.2)

5 (0.5)

 < 0.001

Other cancer, yes, n (%)

136 (5.6)

87 (6.3)

49 (4.7)

 < 0.001

Surgery, yes, n (%)

1492 (61.6)

923 (66.5)

569 (54.9)

 < 0.001

Radiotherapy, yes, n (%)

2114 (87.2)

1203 (86.7)

911 (87.8)

0.452

Chemotherapy, yes, n (%)

897 (37.0)

534 (38.5)

363 (35.0)

0.085

  1. BMI Body mass index, PG-SGA Patients-generated subjective nutritional assessment, KPS Karnofsky performance status Scale, TP Total protein, Scr Serum creatinine, Alb Albumin, Tch Total cholesterol, CRP C-reactive protein, Glu Glucose, Hb Hemoglobin, N Neutrophils, L lymphocytes, RBC Red blood cell, PLT Platelets